Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study

References

• World Health Organization: WHO Coronavirus (COVID-19) Dashboard. [cited 2022 May 2]. Available from: https://covid19.who.int/.
   Google Scholar
• World Health Organization: Tracking SARS-CoV-2 variants. [cited 2022 July 16]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention: Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. [cited 2022 May 2]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.
   Google Scholar
• European Centre for Disease Prevention and Control: Risk factors and risk groups. [cited 2022 May 2]. Available from: https://www.ecdc.europa.eu/en/covid-19/latest-evidence/risk-factors-risk-groups.
   Google Scholar
• National Institutes of Health: Coronavirus Disease. (2019). (COVID-19) Treatment Guidelines. [cited 2022 May 2]. Available from: https://www.covid19treatmentguidelines.nih.gov/.
   Google Scholar
• Kim L, Garg S, O’Halloran A, et al. Risk factors for intensive care unit admission and In-hospital mortality Among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). Clin Infect Dis. 2021;72(9):e206–e214. doi:10.1093/cid/ciaa1012.
   PubMed Web of Science ®Google Scholar
• Berenguer J, Ryan P, Rodríguez-Baño J, et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020;26(11):1525–1536. doi:10.1016/j.cmi.2020.07.024.
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes Among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052–2059.
   PubMed Web of Science ®Google Scholar
• Fried MW, Crawford JM, Mospan AR, et al. Patient characteristics and outcomes of 11 721 patients With coronavirus disease 2019 (COVID-19) hospitalized across the United States. Clin Infect Dis. 2021;72(10):e558–e565. doi:10.1093/cid/ciaa1268.
   PubMed Web of Science ®Google Scholar
• Navaratnam AV, Gray WK, Day J, et al. Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data. Lancet Respir Med. 2021;9(4):397–406. doi:10.1016/S2213-2600(20)30579-8.
   PubMed Web of Science ®Google Scholar
• Omrani AS, Almaslamani MA, Daghfal J, et al. The first consecutive 5000 patients with coronavirus disease 2019 from Qatar; a nation-wide cohort study. BMC Infect Dis. 2020;20(1):777.
   PubMed Web of Science ®Google Scholar
• Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York city: prospective cohort study. BMJ. 2020;369:m1966.
   PubMed Web of Science ®Google Scholar
• Gottlieb M, Sansom S, Frankenberger C, et al. Clinical course and factors associated With hospitalization and critical illness Among COVID-19 patients in Chicago, Illinois. Acad Emerg Med. 2020;27(10):963–973. doi:10.1111/acem.14104.
   PubMed Web of Science ®Google Scholar
• Kim DW, Byeon KH, Kim J, et al. The correlation of comorbidities on the mortality in patients with COVID-19: an observational study based on the Korean national health insurance Big data. J Korean Med Sci. 2020;35(26):e243, doi:10.3346/jkms.2020.35.e243.
   PubMed Web of Science ®Google Scholar
• Soares RCM, Mattos LR, Raposo LM. Risk factors for hospitalization and mortality due to COVID-19 in espírito santo state, Brazil. Am J Trop Med Hyg. 2020;103(3):1184–1190. doi:10.4269/ajtmh.20-0483.
   PubMed Web of Science ®Google Scholar
• Harrison SL, Fazio-Eynullayeva E, Lane DA, et al. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. 2020;17(9):e1003321, doi:10.1371/journal.pmed.1003321.
   PubMed Web of Science ®Google Scholar
• Parra-Bracamonte GM, Lopez-Villalobos N, Parra-Bracamonte FE. Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. Ann Epidemiol. 2020;52:93–98.e92.
   PubMed Web of Science ®Google Scholar
• Reilev M, Kristensen KB, Pottegård A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49(5):1468–1481. doi:10.1093/ije/dyaa140.
   PubMed Web of Science ®Google Scholar
• Hirose N, Ishimaru M, Morita K, et al. A review of studies using the Japanese national database of health insurance claims and specific health checkups. Annals of Clinical Epidemiology. 2020;2(1):13–26. doi:10.37737/ace.2.1_13.
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83.
   PubMed Web of Science ®Google Scholar
• WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–e197.
   PubMed Web of Science ®Google Scholar
• Tokyo Metropolitan Government: Tokyo Metropolitan New Coronavirus Monitoring Conference and Analysis Materials. [cited 2022 Nov 8]. Available from: https://www.bousai.metro.tokyo.lg.jp/taisaku/saigai/1013388/index.html.
   Google Scholar
• Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV; 2, delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22(1):35–42.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693–704. doi:10.1056/NEJMoa2021436.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021;384(9):795–807. doi:10.1056/NEJMoa2031994.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med. 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764.
   PubMed Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA. 2020;324(11):1048–1057. doi:10.1001/jama.2020.16349.
   PubMed Web of Science ®Google Scholar
• Kumar VJ, Banu S, Sasikala M, et al. Effectiveness of REGEN-COV antibody cocktail against the B.1.617.2 (delta) variant of SARS-CoV-2: A cohort study. J Intern Med. 2022;291(3):380–383.
   PubMed Web of Science ®Google Scholar
• Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. J Clin Virol. 2021;145:105026.
   PubMed Web of Science ®Google Scholar
• Carrillo-Vega MF, Salinas-Escudero G, García-Peña C, et al. Early estimation of the risk factors for hospitalization and mortality by COVID-19 in Mexico. PLoS One. 2020;15(9):e0238905.
   PubMed Web of Science ®Google Scholar
• Martos-Benítez FD, Soler-Morejón CD, García-Del Barco D. Chronic comorbidities and clinical outcomes in patients with and without COVID-19: a large population-based study using national administrative healthcare open data of Mexico. Intern Emerg Med. 2021;16(6):1507–1517. doi:10.1007/s11739-020-02597-5.
   PubMed Web of Science ®Google Scholar
• Van Gerwen M, Alsen M, Little C, et al. Risk factors and outcomes of COVID-19 in New York city; a retrospective cohort study. J Med Virol. 2021;93(2):907–915. doi:10.1002/jmv.26337.
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Rabe AP, Loke WJ, et al. Epidemiology, healthcare resource utilization, and mortality of asthma and COPD in COVID-19: A systematic literature review and meta-analyses. J Asthma Allergy. 2022;15:811–825. doi:10.2147/JAA.S360985.
   PubMed Web of Science ®Google Scholar
• Sunjaya AP, Allida SM, Di Tanna GL, et al. Asthma and COVID-19 risk: a systematic review and meta-analysis. Eur Respir J. 2022;59(3):2101209. doi:10.1183/13993003.01209-2021
   PubMed Web of Science ®Google Scholar